Organogenesis Holdings Inc. (ORGO)
Nasdaq · Healthcare · Drug Manufacturers - Specialty & Generic
$1.29−3.01%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $166M
- 52-week range
- $1.27 – $7.08
- 52-week change
- −67.87%
- EPS (trailing)
- −$0.83
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $564M (+17.04%)
- Net income
- $37.0M
- Operating margin
- 7.9%
- Diluted EPS
- $0.15
- Free cash flow
- −$24.5M
From the company’s annual report on SEC EDGAR.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. Its advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, VIA Matrix, and SimpliMax are placental tissue grafts used to treat chronic and acute wounds that can be stored at room temperature.
Headquarters: Canton, United States · 854 employees · organogenesis.com